-$1.66 Earnings Per Share Expected for Axovant Sciences Ltd (AXGT) This Quarter

Analysts forecast that Axovant Sciences Ltd (NASDAQ:AXGT) will post earnings per share (EPS) of ($1.66) for the current quarter, Zacks reports. Zero analysts have made estimates for Axovant Sciences’ earnings. The lowest EPS estimate is ($2.24) and the highest is ($1.28). Axovant Sciences posted earnings per share of ($1.84) during the same quarter last year, which would indicate a positive year over year growth rate of 9.8%. The company is scheduled to announce its next quarterly earnings report on Monday, June 10th.

On average, analysts expect that Axovant Sciences will report full-year earnings of ($9.42) per share for the current financial year, with EPS estimates ranging from ($10.00) to ($8.96). For the next financial year, analysts forecast that the business will report earnings of ($7.00) per share, with EPS estimates ranging from ($9.92) to ($5.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Axovant Sciences.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th. JMP Securities reaffirmed an “outperform” rating and set a $48.00 target price (down from $64.00) on shares of Axovant Sciences in a research note on Monday, March 11th. Evercore ISI assumed coverage on shares of Axovant Sciences in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Chardan Capital upgraded shares of Axovant Sciences from a “neutral” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Monday, March 11th. Finally, Cowen reiterated a “hold” rating on shares of Axovant Sciences in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $40.20.

Institutional investors and hedge funds have recently made changes to their positions in the business. ExodusPoint Capital Management LP acquired a new position in shares of Axovant Sciences in the first quarter valued at approximately $41,000. Jane Street Group LLC acquired a new position in Axovant Sciences during the 1st quarter worth approximately $48,000. Marshall Wace LLP acquired a new position in Axovant Sciences during the 1st quarter worth approximately $272,000. Morgan Stanley acquired a new position in Axovant Sciences during the 1st quarter worth approximately $291,000. Finally, Macquarie Group Ltd. acquired a new position in Axovant Sciences during the 1st quarter worth approximately $1,150,000. Institutional investors and hedge funds own 16.49% of the company’s stock.

Shares of AXGT stock opened at $7.70 on Friday. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 1.24. Axovant Sciences has a 12 month low of $7.16 and a 12 month high of $52.72. The stock has a market cap of $175.41 million, a price-to-earnings ratio of -0.47 and a beta of 1.22.

Axovant Sciences Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

See Also: What is net income?

Get a free copy of the Zacks research report on Axovant Sciences (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.